ERBB2 and breast carcinoma: In this study, we updated and validated a previously developed model [16] to evaluate the population-level, long-term effects of chemotherapy in women diagnosed with node positive, hormone receptor positive, HER2-negative breast cancer, and recurrence scores 0–25 by race and ethnicity.